Skip to content

Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.

Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04205864
Enrollment
72
Registered
2019-12-20
Start date
2019-12-20
Completion date
2020-07-02
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrium Cancer, Lymphocele, Lymphocele After Surgical Procedure

Brief summary

To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel matrix used and not used during pelvic lymph node dissection.

Detailed description

Pelvic lymph node dissection is the most accurate staging tool to determine lymph node involvement in endometrial cancer. Lymphoceles developed after surgery can cause serious morbidity, additional costs and delays in chemotherapy or radiotherapy. In this study, conventional pelvic lymphadenectomy will be compared with thrombin gel matrix application after pelvic lymphadenectomy. Our goal is to prospectively assess the lymphostatic effect of thrombin gel matrix in endometrial cancer patients undergoing pelvic lymph node dissection.

Interventions

Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy

PROCEDUREConventional Pelvic lymphadenectomy

Conventional Pelvic lymphadenectomy

Sponsors

Kocaeli University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Application of Thrombin gel matrix after Pelvic lymphadenectomy. And compare this application with Conventional Pelvic Lymphadenectomy.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Endometrial cancer patients who need laparotomic bilateral PLND * Patients suitable for surgery

Exclusion criteria

* Previous pelvic surgery * Previous Chemotherapy or Radiotherapy * Patients who undergo only lymph node sampling * Patients who have not signed Informed Consent

Design outcomes

Primary

MeasureTime frameDescription
Frequency of pelvic lymphocelepost-operative 2th monthFrequency pelvic lymphocele at post-operative 2th month

Secondary

MeasureTime frameDescription
Volume of radiographic lymphocelespost-operative 2th monthVolume of lymphocele detected with radiographic imagining at post-operative 2th month (the two largest dimensions measured in centimetres)
duration of postoperative drainage catheterup to post-operative 1 weekduration of postoperative drainage catheter
Postoperative drain amount (ml: milliliters)with 1 weeks after surgeryPostoperative drain amount (ml: milliliters)

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026